These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15210897)

  • 1. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
    Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A
    Neurology; 2004 Jun; 62(12):2288-90. PubMed ID: 15210897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.
    Briani C; Zara G; Rondinone R; Iaccarino L; Ruggero S; Toffanin E; Ermani M; Ghirardello A; Zampieri S; Sarzi-Puttini P; Doria A
    Autoimmunity; 2005 Nov; 38(7):549-55. PubMed ID: 16373260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
    Yuki EFN; Soares R; Kupa LVK; Heise CO; Aikawa NE; Arnone M; Romiti R; Pedrosa TDN; Silva CAAD; Bonfa E; Pasoto SG
    Lupus; 2021 May; 30(6):956-964. PubMed ID: 33657919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
    Chasset F; Tounsi T; Cesbron E; Barbaud A; Francès C; Arnaud L
    J Am Acad Dermatol; 2018 Feb; 78(2):342-350.e4. PubMed ID: 28989111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide neuropathy: too much or too long?
    Apfel SC; Zochodne DW
    Neurology; 2004 Jun; 62(12):2158-9. PubMed ID: 15210874
    [No Abstract]   [Full Text] [Related]  

  • 7. Thalidomide-induced orofacial neuropathy.
    Anyanwu CO; Stewart CL; Werth VP
    J Clin Rheumatol; 2014 Oct; 20(7):399-400. PubMed ID: 25275775
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients.
    Coelho A; Souto MI; Cardoso CR; Salgado DR; Schmal TR; Waddington Cruz M; de Souza Papi JA
    Lupus; 2005; 14(6):434-9. PubMed ID: 16038106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
    Thomson KF; Goodfield MJ
    J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation.
    Groenen PS; van Helmond N; Chapman KB
    Pain Med; 2019 Apr; 20(4):857-859. PubMed ID: 30412243
    [No Abstract]   [Full Text] [Related]  

  • 11. Thalidomide in cutaneous lupus erythematosus.
    Pelle MT; Werth VP
    Am J Clin Dermatol; 2003; 4(6):379-87. PubMed ID: 12762830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and sensory neurotoxicity: a neurophysiological study.
    Zara G; Ermani M; Rondinone R; Arienti S; Doria A
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1258-61. PubMed ID: 18450790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
    Wang D; Chen H; Wang S; Zou Y; Li J; Pan J; Wang X; Ren T; Zhang Y; Chen Z; Feng X; Sun L
    Clin Rheumatol; 2016 Jun; 35(6):1521-7. PubMed ID: 27097914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide-induced neuropathy.
    Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G
    Neurology; 2002 Dec; 59(12):1872-5. PubMed ID: 12499476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thalidomide therapy of cutaneous lupus erythematosus].
    Bohmeyer J; Achenbach A; Westenberger M; Stadler R
    Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
    Baret I; De Haes P
    J Dermatolog Treat; 2015 Apr; 26(2):173-7. PubMed ID: 24731053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.
    Cesbron E; Bessis D; Jachiet M; Lipsker D; Cordel N; Bouaziz JD; Bagot M; Arnaud L; Barbaud A; Francès C; Chasset F;
    J Am Acad Dermatol; 2018 Jul; 79(1):162-165. PubMed ID: 29496481
    [No Abstract]   [Full Text] [Related]  

  • 20. [Thalidomide therapy for discoid lupus erythematosus].
    Lyakhovisky A; Baum S; Shpiro D; Salomon M; Trau H
    Harefuah; 2006 Jul; 145(7):489-92, 551. PubMed ID: 16900736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.